3
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Micronized Purified Flavonoid Fraction and the Treatment of Chronic Venous Insufficiency: Microcirculatory Mechanisms

Pages S35-S40 | Published online: 10 Jul 2009

References

  • Behar A, Lagrue G, Cohen-Boulakia F, Baillet J. (1988). Study of capillary filtration by double label�ling I131 albumin and Tc99m red cells. Application to the pharmacodynamic activity of Daflon 500 mg. Int Angiol 7\(supp 2):35�38.
  • Belcaro G, Cesarone MR, De Sanctis MT, Incandela L, Laurora G, Fevrier B, Wargon C, De Gregoris P. (1995). Laser Doppler and transcutaneous oximetry: Modern investigations to assess drug efficacy in chronic venous insufficiency. Int J Microcirc 15\(suppl 1):45�49.
  • Bouskela E, Donyo K. (1997). Effects of oral admin�istration of purified micronized flavonoid fraction on increased microvascular permeability induced by various agents and on ischaemia-reperfusion in the hamster cheek pouch. Angiology 48:391�399.
  • Bouskela E, Donyo KA, Verbeuren TJ. (1995) Effects of Daflon 500 mg on increased microvascular perme�ability in normal hamsters. Int J Microcirc 15:22�26.
  • Burand KG, Whimster I, Naidoo A, Browse NL. (1982). Pericapillary fibrin in the ulcer-bearing skin of the leg: the cause of lipodermatosclerosis and ve�nous ulceration. Br Med J 285:1071�1072.
  • Cospite M, Cospite V. (1992). Treatment of haemorrhoids with Daflon 500 mg. Phlebology 7\(suppl 2):53�56.
  • Cospite M, Dominici A. (1989). Double blind study of the pharmacodynamic and clinical advantages of 5682SE in venous insufficiency. Advantages of the new micronized form. Angiology 8\(suppl 4):61�65.
  • Cotonat A, Cotonat J. (1989). Lymphagogue and pul�satile activities of Daflon 500 mg on canine thoracic lymph duct. Int Angiol 8\(suppl 4):15�18.
  • Franks PJ, Oldroyd MI, Dickson D, Sharp EJ, Moffatt CJ. Risk factors for leg ulcer recurrence: A random�ized trial of two types of compression stocking. Age Ageing 24:490�494.
  • Friesenecker B, Tsai AG, Intaglietta M. (1995). Cel�lular basis of inflammation, oedema and the activity of Daflon 500 mg. Int J Microcirc 15:17�21.
  • Galley P, Thiollet M. (1993). A double blind, placebo controlled trial of a new veno-active flavonoid frac�tion (S 5682) in the treatment of symptomatic capil�lary fragility. Int Angiol 12:69�72.
  • Gargouil YM, Perdrix L, Chapelain B, Gaborieau R. (1989). Effects of Daflon 500 mg on bovine vessels contractility. Int Angiol 8\(suppl 4):19�22.
  • Ghauri AS, Nyamekye 1, Grabs AJ, Farndon JR, Whyman MR, Poskitt KR. (1998). Influence of a spe�cialised leg ulcer service and venous surgery on the outcome of venous leg ulcers. Eur J Vasc Endovasc Surg 16:238�244.
  • Guilhou JJ, Dereure O, Marzin L, Ouvry P, Zuccarelli F, Debure C, Van Landuyt H, Gillet-Terver MN, Guillot B, Levesque H, Mignot J, Pillion G, Fevrier B, Dubeaux D. (1997). Efficacy of Daflon 500 mg in venous leg ulcer healing: A double-blind, randomised, controlled versus placebo trial in 107 patients. Angi-ology 48:77�85.
  • Halliwell B. (2000). Antioxidant activity and other biological effects of flavonoids. In: Rice-Evans CA, ed. Wake up to Flavonoids. (CA Rice-Evans, ed.) Royal Society of Medicine Press Ltd. pp. 13�23.
  • Ibeguna V, Nicolaides AN, Sowade O, Leon M, Ger-oulakos G. (1997). Venous elasticity after treatment with Daflon 500 mg. Angiology 48:45�49.
  • Jean T, Bodinier MC. (1994). Mediators involved in inflammation: Effects of Daflon 500 mg on their re�lease. Angiology 45(6 pt 2):554�559.
  • Johnston AM, Paul HJ, Young CG. (1994). Effects of micronization on digestive absorption of diosmin. Phlebology 9\(supp 1):4�6.
  • Jovanovic SV, Steenken S, Simic MC, Hara Y. (1998). Antioxidant properties of flavonoids: Reduc�tion potentials and electron transfer reactions of fla-vonoid radicals. In: Flavonoids in Health and Dis�ease. (CA Rice-Evans and L Packer, Eds.) Marcel Dekker. New York. pp. 137�169.
  • Juteau N, Bakri F, Pomies JP, Foulon C, Rigaudy P, Pillion G, Lange G, Genre O, Cron JP. (1995). The human saphenous vein in pharmacology: Effect of a new micronized flavonoidic fraction (Daflon 500 mg) on norepinephrine induced contraction. Int Angiol 14 (3 suppl 1):8�13.
  • Korthuis RJ, Gute DC. (1999). Adhesion molecule ex�pression in postischaemic microvascular dysfunction activity of a micronized purified flavonoid fraction. J Vasc Res 36\(suppl 1):15�23.
  • Korthuis RJ, Gute DC. (1997). Post-ischaemic leuco-cyte-endothelial cell interactions and microvascular barrier dysfunction in skeletal muscle: Cellular mechanisms and effect of Daflon 500 mg. Int J Mi-crocirc: Clin Exp 17\(suppl 1):11�17.
  • Laurent R, Gilly R, Frileux C. (1998). Clinical evalu�ation of a venotropic drug in man. Example of Daflon 500 mg. Int Angiol 7(suppl to no 2):39�43.
  • Lonchampt M, Guardiola B, Sicot N, Bertrand M, Perdrix L, Duhault J. (1989). Protective effect of a purified flavonoid fraction against reactive oxygen radicals. In vivo and in vitro study. Arzneimittelfor-schung/Drug Res 39:882�885.
  • McHale NG, Hollywood MA. (1994). Control of lym�phatic pumping: Interest of Daflon 500 mg. Phlebol-ogy 9\(suppl 1):23�25.
  • Ramelet AA, Monti M. (1994). Phlebologie, 3rd ed. Masson. Paris. pp. 71�77.
  • Rice-Evans CA, Miller NJ, Bolwell PG, Bramley PM, Pridham JB. (1995). The relative antioxidant activi�ties of plant-derived polyphenolic flavonoids. Free Radic Res 22(4):375�383.
  • Rice-Evans CA, Miller NJ, Paganga G. (1996). Struc-ture-antioxidant activity relationships of flavonoids and phenolic acids. Free Radic Biol Med 20:933�956.
  • Saharay M, Shields DA, Georgiannos SN, Porter JB, Scurr JH, Coleridge Smith PD. (1998). Endothelial activation in patients with chronic venous disease. Eur J Vasc Endovasc Surg 15:342�349.
  • Scriven JM, Hartshorne T, Thrush AJ, Bell PR, Naylor AR, London NJ. (1998). Role of saphenous vein sur�gery in the treatment of venous ulceration. Br J Surg 85:781�784.
  • Shoab SS, Porter J, Scurr JH, Coleridge Smith PD. (1999). Endothelial activation response to oral mi-cronised flavonoid therapy in patients with chronic venous disease�A prospective study. Eur J Vasc En-dovasc Surg 17:313�318.
  • Shoab SS, Porter J, Scurr JH, Coleridge Smith PD. (2000). Effect of oral micronized purified flavonoid fraction treatment on leukocyte adhesion molecule expression in patients with chronic venous disease: A pilot study. J Vasc Surg 31:456�461.
  • Shoab SS, Scurr JH, Coleridge Smith PD. (1998). Increased plasma vascular endothelial growth factor among patients with chronic venous disease. J Vasc Surg 28:535�540.
  • Shoab SS, Scurr JH, Coleridge Smith PD. (1999). Plasma VEGF as a marker of therapy in patients with chronic venous disease treated with oral micronised flavonoid fraction�A pilot study. Eur J Vasc Endo-vasc Surg 18:334�338.
  • Shami SK, Sarin S, Cheatle TR, Coleridge Smith PD, Scurr JH. (1993). Venous ulcers and the superficial venous system. J Vasc Surg 17:487�490.
  • Takase S, Delano FA, Lerond L, Bergan JJ, Schmid-Scho�nbein GW. (1999). Inflammation in chronic ve�nous insufficiency: Is the problem insurmountable? J Vasc Res 36\(suppl 1):3�10.
  • Takase S, Delano FA, Lerond L, Bergan JJ, Schmid-Scho�nbein GW. (2000). The inflammatory reaction during venous hypertension in the rat. Microcircula�tion 7:41�52.
  • van Acker SA, Tromp MN, Haenen GR, van der Vijgh WJ, Bast A. (1995). Flavonoids as scavengers of nitric oxide radical. Biochem Biophys Res Commun 214(3): 755�759.
  • VEINES Taskforce. (1999). The management of chronic venous disorders of the leg: An evidenced-based report of an international task force. Phlebol-ogy 14\(suppl 1):92; 67.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.